(Q37794991)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

review article

0 references

title

Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Joseph Gligorov

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Michael Gnant

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Henning T Mouridsen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Matthias W Beckmann

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Kimberly Blackwell

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Julie Doughty

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Antonio Llombart-Cussac

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Andre Robidoux

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Beat Thürlimann

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

30 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883112%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

14 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

1825-1836

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883112%20AND%20SRC:MED&resulttype=core&format=json

Duration of adjuvant endocrine therapy of breast cancer: how much is enough?

14 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

The importance of distant metastases in hormone-sensitive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Intergroup Exemestane Study mature analysis: overall survival data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Letrozole in the extended adjuvant setting: MA.17

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Aromatase inhibition: translation into a successful therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

CYP2D6 and tamoxifen: DNA matters in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Alternative indications for bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Exploring the anti-tumour activity of bisphosphonates in early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Antitumor effects of bisphosphonates: promising preclinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Practical guidance for the management of aromatase inhibitor-associated bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160

Aromatase inhibitors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.160